Mar 19 |
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
|
Mar 19 |
Harrow: Q4 Earnings Insights
|
Mar 18 |
Harrow Health Q4 2023 Earnings Preview
|
Mar 13 |
Harrow (HROW) Fell on Lowering the Guidance
|
Mar 5 |
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
|
Feb 21 |
Here’s How Harrow (HROW) Weighed on SRK Capital’s Performance
|
Feb 19 |
Harrow's Drug Iheezo Is Off To A Great Start
|
Feb 15 |
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
|
Feb 5 |
Harrow: Hedge Downside Risk With The 11.5% Yielding Baby Bonds
|
Jan 30 |
Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
|